---
title: "INSILICO and United Therapeutics complete the first administration of a new CKD anemia drug in Phase I clinical trial"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/278004424.md"
description: "INSILICO announced that the Phase I clinical trial of the CKD anemia new drug ISM4808, in collaboration with TaiJing Pharmaceuticals, has completed the enrollment and dosing of the first subject, marking the achievement of the first milestone in the partnership. This project is an AI-driven PHD inhibitor, designed as a randomized, double-blind, placebo-controlled trial to evaluate the drug's safety, tolerability, and pharmacokinetic characteristics. According to the agreement, TaiJing has obtained exclusive development rights for the drug in the Greater China region, and INSILICO will receive an upfront payment and milestone payments, with the total transaction amount reaching tens of millions of dollars"
datetime: "2026-03-06T00:15:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/278004424.md)
  - [en](https://longbridge.com/en/news/278004424.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/278004424.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/278004424.md) | [繁體中文](https://longbridge.com/zh-HK/news/278004424.md)


# INSILICO and United Therapeutics complete the first administration of a new CKD anemia drug in Phase I clinical trial

According to a report from Economic Information Agency on the 6th, INSILICO (03696) announced that its innovative drug ISM4808 for chronic kidney disease (CKD) anemia, previously authorized to TaiJing Pharmaceutical Development Holdings Co., Ltd., has made research progress, with the first subject enrolled and dosed in the related Phase I clinical trial, marking the achievement of the first milestone in the collaboration.

The company stated that the project is a PHD inhibitor developed through artificial intelligence. This Phase I clinical trial employs a randomized, double-blind, placebo-controlled design, including both single ascending dose (SAD) and multiple ascending dose (MAD) parts, aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of ISM4808 in healthy adult subjects.

\\\* The pipeline licensing cooperation potential transaction involves tens of millions of dollars \*

Data shows that INSILICO reached a pipeline licensing cooperation for the ISM4808 project with TaiJing in December 2025. According to the agreement, TaiJing obtains exclusive development, commercialization, and sublicensing rights for the drug in the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan). In return, INSILICO will receive an upfront payment, as well as milestone payments based on research progress and sales performance, and will be entitled to tiered royalties calculated based on net sales, with the total transaction amount reaching tens of millions of dollars. (eh)

### 相关股票

- [INSILICO (03696.HK)](https://longbridge.com/zh-CN/quote/03696.HK.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-CN/quote/516500.CN.md)
- [TIGERMED (03347.HK)](https://longbridge.com/zh-CN/quote/03347.HK.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-CN/quote/159837.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-CN/quote/516930.CN.md)

## 相关资讯与研究

- [InSilico Medicine Boosts AI Platform and Advances Clinical Pipeline](https://longbridge.com/zh-CN/news/280916373.md)
- [InSilico Expands AI-Driven CNS Collaboration With Tenacia in USD94.75 Million Deal](https://longbridge.com/zh-CN/news/280541264.md)
- [InSilico Out-licensed Drug ISM4808 Begins Clinical Trial](https://longbridge.com/zh-CN/news/278010381.md)
- [InSilico Medicine Doses First Patient in ISM5411 Study](https://longbridge.com/zh-CN/news/272203151.md)
- [Insilico Medicine Unveils AI-Designed ISM5059 as Preclinical NLRP3 Inhibitor Candidate](https://longbridge.com/zh-CN/news/274977240.md)